Abstracts Archive - Page 1272 of 2607 - ACR Meeting Abstracts

Abstract Number: 1285 • 2018 ACR/ARHP Annual Meeting
Comparision of Urate Burden in Well and Poorly Controlled Gout Patients: A Dual-Energy CT Study
Min Kyung Chung¹, Hyeran Hyun², Ji Young Hwang² and Jisoo Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Radiology, Ewha Womans University School of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Dual-energy computed tomography (DECT) allows sensitive and quantative detection of monosodium urate (MSU) crystals in patients with gout. Although its usefulness in diagnosing gout…
Abstract Number: 1286 • 2018 ACR/ARHP Annual Meeting
Pretreatment and Coadministration with Methotrexate Improved Durability of Pegloticase (Krystexxa) Response: A Prospective, Proof-of-Concept, Case Series
John Botson¹ and Jeff Peterson², ¹Orthopedic Physicians Alaska, Anchorage, AK, ²Western Washington Arthritis Clinic, Bothell, WA
Background/Purpose: Pegloticase is a recombinant DNA-produced porcine-like uricase enzyme which metabolizes relatively insoluble urate to highly soluble allantoin. It is used in the treatment of…
Abstract Number: 1287 • 2018 ACR/ARHP Annual Meeting
Strong Impact of Dysfunctional Variants of ABCG2 on Hyperuricemia and Gout in Children and Adolescents
Blanka Stiburkova^1,2, Katerina Pavelcova^1,3, Marketa Pavlikova¹ and Karel Pavelka⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Department of Pediatrics and Adolescent Medicine, Charles University and General University Hospital in Prague, First Faculty of Medicine, Prague, Czech Republic, ³Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Na Slupi 4, Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: Common dysfunctional variants of ABCG2, a high-capacity urate transporter gene, that result in decreased urate excretion, are major causes of hyperuricemia and gout. However,…
Abstract Number: 1288 • 2018 ACR/ARHP Annual Meeting
Association between Musculoskeletal Ultrasonography and Bone Remodeling Markers and the Role of Ultrasonography on Monitoring Treatment Responsiveness in Patients with Gout and Hyperuricemia
Ya-dan Zou^1,2, Ya-nan Fei¹, Hui Gao³, Lin-feng Xie¹, Yu-chao Zhong¹ and Xuewu Zhang³, ¹Peking University People's Hospital, Beijing, China, ²Peking University International Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Musculoskeletal ultrasonography (US) is an invasive method to identify gout related bone damage, while Dickkopf-1 (DKK-1) and receptor activator of nuclear factor-κB ligand（RANKL）are bone…
Abstract Number: 1289 • 2018 ACR/ARHP Annual Meeting
Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplant Population
Andrew Milgroom¹, Mara Onita Lenco¹, Kevin Francis¹, Jeffrey D. Kent², Brian LaMoreaux³ and Brian F. Mandell⁴, ¹Trinity Partners, Waltham, MA, ²Medical Affairs, Horizon Pharma USA, Inc, Lake Forest, IL, ³Horizon Pharma USA, Inc, Lake Forest, IL, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Gout is a frequent co-morbidity of solid organ transplant (SOT). Cyclosporine (CsA) is often cited as the main cause of gout in SOT, as…
Abstract Number: 1290 • 2018 ACR/ARHP Annual Meeting
Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study
Silvia Rollefstad¹, Till Uhlig^2,3, Lars Fridtjof Karoliussen³, Hilde B. Hammer⁴ and Anne Grete Semb⁵, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²University of Oslo, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Systemic inflammation and atherosclerosis in patients with gout. Results from the NOR-Gout studyBackground/Purpose: The association between gout and cardiovascular disease (CVD) is well known, whereas…
Abstract Number: 1291 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Anakinra in Congestive Heart Failure Patients, Including Lvad, with Acute Gouty Arthritis: A Retrospective Study of 36 Patients at an Academic Medical Center
Arash Hassantoufighi¹, Paloma Alejandro², Christopher E. Collins², Florina Constantinescu² and Juhi Bhargava³, ¹Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, washington, DC, ²Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ³Internal Medicine, MedStar Washington Hospital Center/Georgetown University Medical Center, washington, DC
Background/Purpose: Gout is the most common inflammatory arthritis worldwide and many patients with gout are ‘complicated’ by multiple comorbidities including metabolic syndrome, renal disease and…
Abstract Number: 1292 • 2018 ACR/ARHP Annual Meeting
HLA-B*58:01 Genotype and the Risk of Allopurinol-Associated Severe Cutaneous Adverse Reactions in a Predominately Black or African American Population with Advanced Chronic Kidney Disease
Sarah Ford¹, Pamela Kimball¹, Gaurav Gupta¹ and Nehal Shah², ¹Virginia Commonwealth University, Richmond, VA, ²Medicine/Rheumatology, Virginia Commonwealth University, Richmond, VA
Background/Purpose: Allopurinol is the first line urate lowering drug used for treatment of gout. Its most feared side effect includes development of hypersensitivity drug reactions…
Abstract Number: 1293 • 2018 ACR/ARHP Annual Meeting
Identification of New and Rare Variants in ABCG2, SLC22A1 and ALDH16A1 Genes in Crystal-Proven Early-Onset Gout
Corinne Collet¹, Hélène Morel¹, Manon Ricquebourg¹, Martine Cohen-Solal², Jean-Louis Laplanche¹, Tristan Pascart³, Thomas Bardin⁴, Frederic Liote⁵, Pascal Richette⁶ and Hang-Korng Ea⁷, ¹biochemistry, Laribosiere hospital, Paris, France, ²INSERM UMR1132, Paris Diderot University, Paris, France, ³Rheumatology, Groupe Hospitalier de l'Institut Catholique de Lille, Lomme, France, ⁴Rheumatology, Hôpital Lariboisière, Paris, France, ⁵University Paris Diderot, Paris, France, ⁶Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ⁷INSERM UMR1132, Bioscar, University Paris Diderot, PARIS, France
Background/Purpose: Early-onset or juvenile gout (EOG) without hypoxanthine-guanine phosphoribosyltransferase enzyme deficiency (HPRT, OMIM 300323) and not related to familial juvenile hyperuricemic nephropathy (UMOD, OMIM 300323)…
Abstract Number: 1294 • 2018 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin Enables Sustained Reduction of Acute Gout Flares
Rehan Azeem¹, Alan J. Kivitz², Earl Sands¹, Wesley DeHaan Ph.D.³, Lloyd Johnston³ and Takashi Kei Kishimoto³, ¹Selecta Biosciences, Inc, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA, ³Selecta Biosciences, Watertown, MA
Background/Purpose: Pegylated uricases are therapies for treatment of severe chronic gout, particularly for rapid tophi resolution. However, uricases are limited by induction of anti-drug antibodies…
Abstract Number: 1295 • 2018 ACR/ARHP Annual Meeting
Anakinra Is More Effective at Reducing Pain from Acute Crystal Induced Arthritis When Compared to Conventional Therapy: A Retrospective Review at a Tertiary Care Center
Sukhraj Singh¹, Anthony Ocon², Vivek Mehta³, Samah Musa¹ and Ruben Peredo², ¹Internal Medicine, Albany Medical Center, Albany, NY, ²Medicine, Albany Medical Center, Albany, NY, ³Division of Rheumatology, Department of Medicine, Albany Medical College, Albany, NY
Background/Purpose: The management of Acute Crystal-Induced Arthritis (ACIA) relies on NSAIDs, colchicine, and glucocorticoids as conventional therapy. In presence of comorbidities (e.g. renal insufficiency, diabetes…
Abstract Number: 1296 • 2018 ACR/ARHP Annual Meeting
A Novel Potent and Selective Urate Transporter 1 Inhibitor, NC-2700, with pH-Raising Effect on Low Urinary pH
Masuharu Hirano¹, Takafumi Muto¹, Toshitake Hirai², Promsuk Jutabha³, Naohiko Anzai⁴, Toru Horie⁵, Hitoshi Endou⁶ and Tomio Yamakawa⁷, ¹Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ²Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ³Dokkyo Medical University School of Medicine, Tochigi, Japan, ⁴Chiba University Graduate School of Medicine, Chiba, Japan, ⁵Dethree Res Lab Inc., Tsukuba, Japan, ⁶J-Pharma Co., Ltd., Yokohama, Japan, ⁷Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama prefecture, Japan
Background/Purpose: In most patients with gout, renal underexcretion of uric acid is the main mechanism for hyperuricemia. However, for the risk of uric acid kidney…
Abstract Number: 1297 • 2018 ACR/ARHP Annual Meeting
Risk of Dementia in Patients with Gout and the Impact of Urate-Lowering Therapies: A Large Population-Based Cohort Study
Louise Crowley, Alyshah Abdul Sultan, Edward Roddy, Christian Mallen, Joanne Protheroe and Lorna Clarson, Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom
Background/Purpose: Evidence is conflicting concerning dementia risk in gout patients, with hyperuricaemia proposed to exert a neuroprotective effect. Serum urate (sUA) targets guiding urate-lowering therapies…
Abstract Number: 1298 • 2018 ACR/ARHP Annual Meeting
Gout and the Risk of Parkinson’s Disease in Older Adults: A Study of U.S. Medicare Data
Jasvinder A. Singh and John Cleveland, Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: In the presence of limited available data, our objective was to assess the association of gout with the risk of incident Parkinson’s disease (PD)…
Abstract Number: 1299 • 2018 ACR/ARHP Annual Meeting
A Novel Recombinant Oral Urate Oxidase (UrOx) Alln-346 Reduces Severe Hyperuricemia and Normalizes Hyperuricosuria in Nephropathic Urox Knockout (UrOxKO) Mice
Danica Grujic¹, Aditi Desphande¹, Robert Terkeltaub², Nadia Mosiichuk³, Kateryna Goncharva⁴ and Stefan Pirzynowski⁴, ¹R&D, Allena Pharmaceuticals, Newton, MA, ²VA San Diego Healthcare System, San Diego, CA, ³SGPlus and Lund University, Lund, Sweden, ⁴Lund University and SGPlus, Lund, Sweden
A novel recombinant oral urate oxidase (UrOx) ALLN-346 reduces severe hyperuricemia and normalizes hyperuricosuria in nephropathic UrOx knockout (UrOxKO) miceBackground/Purpose: Limitations in efficacy and/or tolerance…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].